Liquet Medical Inc. (#LSIUSA24 Innovator) is on a mission to transform the way vascular disease is treated through localized drug delivery.
The company is developing a novel, easy-to-use, cost-effective solution to address Pulmonary blood clots. The Versus? Catheter introduces a new treatment category, Hemodynamics-Led Thrombolysis (HLT), which has the potential to become the new standard of care for Catheter Directed Thrombolysis.
?? Liquet Medical has recently achieved many recent milestones including:
? Raised $1.8M and looking to close its Seed round
? Awarded non-dilutive grants in recognition of the significance in innovation
? Completed pre-clinical in vitro data showcasing feasibility and proof-of-concept
? Currently finalizing biocompatibility and verification FDA testing
Congratulations to the Liquet Medical team on their recent accomplishments!
We’re excited to announce that CEO, John Schindler has been selected to present at LSI USA ‘24 in Dana Point, California on March 18-22, 2024.
Interested in presenting at LSI USA ‘24? Apply to present today while space is still available. (Link in the comments)